Atea Pharmaceuticals, Inc.AVIRNASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank43
3Y CAGR-12.4%
5Y CAGR+8.6%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-12.4%/yr
vs +104.2%/yr prior
5Y CAGR
+8.6%/yr
Recent deceleration
Acceleration
-116.6pp
Decelerating
Percentile
P43
Within normal range
vs 5Y Ago
1.5x
Solid growth
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$32.76M-32.9%
2024$48.85M-2.1%
2023$49.92M+2.5%
2022$48.71M+6.4%
2021$45.78M+111.6%
2020$21.64M+387.6%
2019$4.44M+58.4%
2018$2.80M-